In a nutshell This study investigated whether the risk of developing melanoma brain metastases (MBM) and survival among patients with MBM has changed since the introduction of more effective therapies. The results found the overall survival for patients with MBM has improved significantly since 2011. Some background In more than 33% of patients...
Read MoreIn a nutshell This study examined the effectiveness of treatment with vemurafenib (Zelboraf) and cobimetinib (Cotellic) in metastatic (spread to other parts of the body) melanoma. Researchers suggested that this combination improves treatment outcomes. Some background PD-L1 is a protein present in the immune system that helps attacking cancer...
Read MoreIn a nutshell This study investigated the long-term safety and effectiveness of dabrafenib (Tafinlar) and trametinib (Mekinist) in metastatic melanoma. Researchers suggested that this treatment increased overall survival in melanoma patients. Some background Some melanoma patients have a mutation (permanent change) in the BRAF gene. Dabrafenib...
Read More
In a nutshell This review examined the effectiveness of dabrafenib (Tafinlar) and trametinib (Mekinist) for BRAF mutated melanoma with brain metastasis. Researchers concluded that this combined treatment is an important therapy option for patients with advanced melanoma. Some background Some melanoma patients have a mutation (permanant change) in...
Read More
In a nutshell This study investigated the effectiveness and safety of combined treatment with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutated stage 3 or 4 melanoma. Researchers suggested that the combination treatment has durable (3 years or more) results. Some background Patients with metastatic (spread to...
Read More
In a nutshell This study reviewed the effectiveness and safety of combined treatment with BRAF and MEK inhibitors in patients with advanced melanoma. Researchers suggested that combined treatment of BRAF and MEK inhibitors was associated with better responses than other treatments. Some background Some melanoma patients have a mutation...
Read MoreIn a nutshell This study examined the effectiveness and safety of vemurafenib (Zelboraf) as treatment for BRAF-mutant metastatic melanoma. Researchers concluded that vemurafenib is an effective treatment option for patients with BRAF-mutated melanoma and brain metastasis (BM; spread to the brain). Some background Over 40% of melanoma patients...
Read More
In a nutshell This trial aims to test safety and effectiveness of the combined treatment with pembrolizumab (Keytruda) and vemurafenib (Zelboraf) in patients with stage 3 or 4 melanoma. The main outcome to be measured will be the response of the tumors to the treatment. This trial is recruiting in Pittsburgh, Pennsylvania (US). The details Tumors...
Read More
In a nutshell This review examined the safety and effectiveness of dabrafenib (Tafinlar) and trametinib (Mekinist) for inoperable metastatic melanoma. Researchers concluded that this combined treatment is an important therapy option for patients with metastatic melanoma. Some background Some melanoma patients have a mutation...
Read More
In a nutshell The authors reviewed the effectiveness of combination therapy of vemurafenib (Zelboraf) and cobimetinib (Cotellic) for the treatment of BRAF-mutated advanced melanoma. The study concluded that a combination treatment with vemurafenib and cobimetinib is an effective option in BRAF-mutant melanoma that...
Read More
In a nutshell The authors evaluated the effectiveness of combination therapy with dabrafenib (Tafinlar) and trametinib (Mekinist) on health-related quality of life in advanced melanoma patients. The authors found out that the combination therapy prolonged survival and decreased treatment-related adverse events. Some background...
Read MoreIn a nutshell The authors aimed to determine the safety profile of vemurafenib in patients with BRAFV600 mutated metastatic melanoma with few treatment options remaining. Some background BRAF (protein in the body that controls cell growth) mutations are one of the key factors that lead to melanoma development. In particular, BRAFV600 (a...
Read More
